Cargando…
Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b
Glycogen storage disease type 1b (GSD1b) is associated with inflammatory bowel disease and congenital neutropenia. Neutropenia in GSD1b is caused by the accumulation of 1,5-anhydroglucitol-6-phosphate. Empagliflozin is an antidiabetic drug that promotes renal excretion of this metabolite. We report...
Autores principales: | Collen, Lauren V., Newburger, Peter E., Snapper, Scott B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684244/ https://www.ncbi.nlm.nih.gov/pubmed/38034420 http://dx.doi.org/10.1097/PG9.0000000000000356 |
Ejemplares similares
-
Crohn-like disease long remission in a pediatric patient with glycogen storage disease type Ib treated with empagliflozin: a case report
por: Calia, Margherita, et al.
Publicado: (2023) -
Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report
por: Rossi, Alessandro, et al.
Publicado: (2021) -
Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients
por: Hexner-Erlichman, Zufit, et al.
Publicado: (2022) -
Food for Thought: Remission of Perianal Pediatric Crohn’s Disease on Specific Carbohydrate Diet Monotherapy
por: Simon, David, et al.
Publicado: (2023) -
Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment
por: Tallis, Eran, et al.
Publicado: (2022)